Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]PSMA-1007 PET for Recurrent Prostate Cancer
NCT04742361Phase 3Completed
- Sponsor
- ABX advanced biochemical compounds
- Start
- Aug 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of radelumin in prostate cancer (PCa), sponsored by ABX advanced biochemical compounds. Primary endpoints: Region-level positive predictive value (PPV) of [18F]PSMA-1007 at 6 months and Patient-level correct detection rate of [18F]PSMA-1007 at 6 months. Started Aug 2021; status: completed.
02
Drugs
radelumin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04742361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04742361.